RT Journal Article
SR Electronic
T1 Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.119.236000
DO 10.2967/jnumed.119.236000
A1 ROUSSEAU, Caroline
A1 Goldenberg, David M
A1 Colombie, Mathilde
A1 Sebille, Jean Charles
A1 Meingan, Philippe
A1 Ferrer, Ludovic
A1 Baumgartner, Pierre
A1 Cerato, Evelyne
A1 Masson, Damien
A1 Campone, Mario
A1 Rauscher, Aurore
A1 Fleury, Vincent
A1 Labbe, Catherine
A1 Faivre-Chauvet, Alain
A1 Frenel, Jean Sebastien
A1 Toquet, Claire
A1 Barbet, Jacques
A1 Sharkey, Robert M
A1 Campion, Loic
A1 Kraeber-Bodere, Francoise
YR 2020
UL http://jnm.snmjournals.org/content/early/2020/03/12/jnumed.119.236000.abstract
AB Purpose: This prospective study evaluated the imaging performance of a novel immunological pretargeting positron-emission tomorgraphy (immuno-PET) method in patients with HER2-negative, carcinoembryonic antigen (CEA)-positive, metastatic breast cancer (BC), compared to computed tomography (CT), bone magnetic resonance imaging (MRI), and 18Fluorodeoxyglucose PET (FDG-PET). Patients and Methods: Twenty-three patients underwent whole-body immuno-PET after injection of 150 MBq 68Ga-IMP288, a histamine-succinyl-glycine peptide given following initial targeting of a trivalent anti-CEA, bispecific, anti-peptide antibody. The gold standards were histology and imaging follow-up. Tumor standard uptake values (SUVmax and SUVmean) were measured, and tumor burden analyzed using Total Tumor Volume (TTV) and Total Lesion Activity (TLA). Results: Total lesion sensitivity of immuno-PET and FDG-PET was 94.7% (1116/1178) and 89.6% (1056/1178), respectively. Immuno-PET had a somewhat higher sensitivity than CT and FDG-PET in lymph nodes (92.4% vs 69.7% and 89.4%, respectively) and liver metastases (97.3% vs 92.1% and 94.8%, respectively), whereas sensitivity was lower for lung metastases (48.3% vs 100% and 75.9%, respectively). Immuno-PET showed higher sensitivity than MRI and FDG-PET for bone lesions (95.8% vs 90.7% and 89.3%, respectively). In contrast to FDG-PET, immuno-PET disclosed brain metastases. Despite equivalent tumor SUVmax, SUVmean, and TTV, TLA was significantly higher with immuno-PET compared to FDG PET (P = 0.009). Conclusion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by 68Ga-IMP288, is a potentially sensitive theranostic imaging method for HER2-negative, CEA-positive, metastatic BC patients, and warrants further research.